Background: problems with the term "double-blind" {#Sec1}
=================================================

"The single biggest problem in communication is the illusion that it has taken place. George Bernard Shaw"

In reports of randomized trials, the use of the term "double-blind" and its derivatives (single- triple-blind, fully blind, and partially blind or masked) is commonly understood to indicate that two groups participating in the trial are kept unaware of which participants are receiving the experimental intervention and which are receiving the control intervention \[[@CR1]--[@CR6]\].

Despite its long and widespread use, however, the term has several problems.

It is ambiguous {#Sec2}
---------------

Agreement about which groups are blinded in a double-blind trial is poor \[[@CR1]--[@CR16]\]. For example, in one study, 91 physicians reported 17 unique combinations of groups (often more than two) that they believed were blinded in a double-blind trial (Table [1](#Tab1){ref-type="table"}), and 25 textbooks contained 9 unique combinations \[[@CR1]\]. Another study of 25 "double-blind trials" published in 16 leading journals identified 5 different combinations of participants, assessors, caregivers, and statisticians as being blinded \[[@CR14]\]. Identifying groups in general terms (e.g., investigators, caregivers) is also ambiguous \[[@CR4]\], especially when individuals have dual roles, such as collecting data and assessing outcomes \[[@CR2], [@CR4]--[@CR6]\]. Table 1Groups reported to be blinded in a double-blind trial. Data are from 2 studies of (![](13063_2020_4607_Figa_HTML.gif){#d30e284}) 130^a^ and (![](13063_2020_4607_Figb_HTML.gif){#d30e290}) 91^b^ physicians and from 2 studies of (![](13063_2020_4607_Figc_HTML.gif){#d30e296}) 83^c^ and (![](13063_2020_4607_Figd_HTML.gif){#d30e303}) 194^d^ published randomized trials described as "double-blinded." Combinations of 3 or more groups were often included in the definition of double-blind^a^Data are from Table 5 in Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. *Clin Trials* 2006;3(4):360-5^b^Data are from the table in Devereaux PJ, Manns BJ, Ghali WA, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. *JAMA*. 2001;285:2000-3. Of 17 unique group combinations, 9 are shown. Presumably, the remaining 8 combinations included "other groups" thought to be blinded (e.g., laboratory technicians, pharmacists)^c^In this study of 83 "double-blind" trials, 49% (41) did not indicate which groups were blinded. Data are from Table 2 in Montori VM, Bhandari M, Devereaux PJ, et al. In the dark: the reporting of blinding status in randomized controlled trials. *J Clin Epidemiol* 2002;55:787-790^d^Data are from Table 1 in Viergever RF, Ghersi D. Information on blinding in registered records of clinical trials. Trials 2012 Nov 15;13:210

It is often uninformative {#Sec3}
-------------------------

Even when using the term in an article, many authors do not identify which groups were blinded or how blinding was implemented \[[@CR1]--[@CR6], [@CR9], [@CR11], [@CR12], [@CR14], [@CR16], [@CR17]\]. Among 83 published trials reported as being double-blind, 41 did not identify any group as being blinded \[[@CR9]\]. Without this information, "readers should remain skeptical about \[blinding's\] effect on bias reduction." \[[@CR2]\].

It can be misleading {#Sec4}
--------------------

Many readers assume---incorrectly---that they know which groups are blinded in a double-blind trial (Table [1](#Tab1){ref-type="table"}) \[[@CR2]--[@CR5], [@CR11], [@CR15], [@CR16]\]. Unfortunately, grossly inadequate reporting allows this assumption to go unchallenged when the article is read. (However, several studies have found that many published trials do not include the details of blinding, even when blinding was adequately implemented \[[@CR4]\].) In 88 (70%) of 126 registered anesthesia trials, the groups or individuals reported to be blinded in the published results differed from those listed in the corresponding protocols \[[@CR16]\].

It is inadequate {#Sec5}
----------------

The suggestion to establish explicit definitions for the term \[[@CR7], [@CR18]\] is complicated by the fact that several groups or individuals can be blinded. Limiting "double-blind" to trials in which only 2 specific groups are blinded leaves other combinations without an equivalent term.

It is often confused with allocation concealment {#Sec6}
------------------------------------------------

In randomized trials, the allocation schedule (the list indicating the group to which the next participant will be assigned, in random order) has to be kept secret to prevent group assignment from being manipulated. That is, allocation concealment minimizes selection bias *before* participants have been assigned to experimental groups, whereas blinding minimizes surveillance, expectation, and ascertainment bias *after* group assignment. Many readers are not aware of this difference \[[@CR2], [@CR5], [@CR6], [@CR8], [@CR12], [@CR13], [@CR15], [@CR18]--[@CR20]\], perhaps because the terms "allocation" and "blinding" indicate neither the similarities nor the differences between the concepts.

It is often mistakenly believed to be required in a randomized trial and to be essential to the trial's validity \[[@CR1], [@CR2], [@CR5], [@CR11], [@CR13], [@CR15], [@CR16], [@CR19]--[@CR21]\] {#Sec7}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

"A randomised trial can be methodologically sound and not be double blind or, conversely, double blind and not methodologically sound." \[[@CR2]\]. Said another way, "Let us examine the placebo somewhat more critically, however, since it and 'double blind' have reached the status of fetishes in our thinking and literature. The Automatic Aura of Respectability, Infallibility, and Scientific Savoir-faire which they possess for many can be easily shown to be undeserved in certain circumstances." \[[@CR21]\].

In some situations, it can be confused with the condition of being without sight \[[@CR2], [@CR5], [@CR12], [@CR20], [@CR22], [@CR23]\] {#Sec8}
---------------------------------------------------------------------------------------------------------------------------------------

Some authors prefer "masking" to "blinding," although the meaning of either term in a clinical trial may not be readily apparent to nonnative English speakers \[[@CR18], [@CR22]\]. Further, some authors use the terms interchangeably \[[@CR5]--[@CR7], [@CR10]--[@CR12], [@CR15], [@CR18], [@CR24], [@CR25]\], others insist that only masking be used \[[@CR17], [@CR20], [@CR23]\], and still others insist that only blinding be used \[[@CR2], [@CR5], [@CR22]\]. In addition, masking is sometimes used to describe *how* treatments are made indistinguishable \[[@CR18], [@CR19], [@CR25], [@CR26]\], whereas blinding usually indicates *which groups* are unaware of treatment assignment \[[@CR1]--[@CR6]\]. Finally, searching the literature for "blinded," "partially blind," or "fully blind" randomized trials also identifies dozens of unwanted citations to the condition of being without sight.

It is unrealistic {#Sec9}
-----------------

The problem with trying to identify in a single term the groups who are blinded in a trial is that the number of pairs is potentially large. The literature identifies 11 groups or individuals who could be blinded: participants, care providers, data collectors and managers, trial managers, pharmacists \[[@CR27]\], laboratory technicians \[[@CR1]\], outcome assessors (who collect data on outcomes), outcome adjudicators (who confirm that an outcome meets established criteria), statisticians \[[@CR2], [@CR4], [@CR6], [@CR11]--[@CR13]\], and sometimes even members of data monitoring and safety committees \[[@CR1], [@CR3], [@CR4], [@CR6], [@CR11], [@CR17]\] and manuscript writers \[[@CR3], [@CR6], [@CR11], [@CR16], [@CR17]\]. These 11 groups can form 55 unique pairs. Even limiting the possibilities to 5 groups commonly recommended for blinding \[[@CR15], [@CR28]\]---participants, care providers, data collectors, outcome assessors, and statisticians---leaves 10 possible combinations.

Proposed solutions {#Sec10}
==================

As near as we can tell, despite the above problems and several calls to abandon the term \[[@CR1], [@CR5], [@CR6], [@CR9], [@CR11], [@CR12], [@CR16], [@CR28]\], only one substitute for double-blinding has been proposed in the literature: "subject- and assessor-blind" \[[@CR29]\]. Aside from being somewhat awkward, the term assumes that double-blinding applies only to subjects and assessors, which, although reasonable, is not uniformly accepted.

The terms "fully blinded" or "partially blinded" do appear in the literature, but not as substitutes for substitutes for double-blinding or single-blinding \[[@CR27]\]. Although both are used in randomized trials, they involve randomly assigning treatments, not groups, and can be applied to subsets of individuals within groups. For example, participants who could receive either an active drug or a placebo would be "fully blinded," whereas participants who know they are receiving an active drug but not which one, would be "partially blinded."

We considered blinding "assignment concealment \[[@CR24]\]" because it accurately indicates that group assignment is what is hidden. It does not imply which groups are involved and has no history of doing so. It also eliminates the blinding-masking controversy and is not associated with other, less-technical meanings. Further, the relationship between blinding and "allocation concealment" is not apparent, but allocation concealment and assignment concealment are two sides of the same coin: they clearly indicate that two different components of the trial are concealed: the allocation schedule and group assignment, one term indicating group concealment before assignment and one after.

However, assignment concealment does not work well as a label. We concluded that "a concealed assignment trial" was unlikely to replace "a blinded trial." Likewise, its use can be awkward: "group assignment was concealed from participants" was unlikely to replace "participants were blinded to treatment." Further, as noted above, for better or worse, the mere use of the term "blinding" is widely considered to indicate study quality, and we concluded that authors would be unwilling to give up using this prized and familiar term. Finally, many people believed that "concealment" should be reserved for, or would be confused with, allocation concealment.

Proposal {#Sec11}
========

The term "blinding" is so firmly established that a simple substitute term, even if we could find one, is unlikely to be acceptable. Instead, we propose two changes in reporting trials described as blinded.

Our first proposal is to eliminate the use of adjectives that modify "blinded": single-, double-, triple-, observer-, personnel-, rater-, observer-, fully or partially blinded, or any other qualifier that would make "blinded" seem more specific than it is. A trial would be described as either blinded or unblinded. Using "blinding" as a verb in a sentence would also be helpful. Such use encourages specificity by requiring a noun, usually which groups were blinded: "We blinded caregivers and data assessors" or "caregivers and data assessors were blinded."

We wholeheartedly endorse the near-universal recommendation that authors report whether or not the trial was blinded \[[@CR4], [@CR10], [@CR14]--[@CR16]\], who was blinded \[[@CR1]--[@CR7], [@CR9]--[@CR13], [@CR15], [@CR16], [@CR19], [@CR20], [@CR22], [@CR30], [@CR31]\], how they were blinded \[[@CR2], [@CR4]--[@CR6], [@CR12], [@CR13], [@CR19], [@CR20], [@CR26], [@CR30], [@CR31]\], and whether the method of blinding was likely to be successful \[[@CR28], [@CR32]\], including the degree of similarity between the experimental and control interventions \[[@CR31]\].

Accordingly, our second proposal is to have all trials described as blinded include the details in a standard "Who Knew" table (Table [2](#Tab2){ref-type="table"}). This table has two parts: a required part and a supplemental part. The required part would indicate whether each of the 6 groups most commonly blinded (the person assigning participants to groups, participants, caregivers, data collectors and managers, outcome assessors, and statisticians) *was or was not blinded*, what information they were blinded to, how blinding was implemented, and whether blinding was maintined during the trial. The supplemental part, used when necessary, would present the same data for any other group or individual who was blinded. Individuals with dual responsibilities, such as caregiving and data collecting, would be identified in the same row heading. If blinding was compromised, authors should report the fact in the table and indicate in the text the potential implications that loss of blinding might have for interpreting the results. Table 2A standard table for reporting the use of blinding in randomized trials of pharmaceutical interventionsGroup or individual blinded^a^Information withheld^b^Method of blinding^c,d^Blinding compromised**Required fields to be completed for all trials described as blinded**Person assigning participants to groupsGroup assignmentConcealed allocation scheduleNoParticipantsGroup assignmentPlacebo medications; sham surgeriesNoCare providersGroup assignmentNot told of group assignmentNoData collectors and managersGroup assignmentNot told of group assignmentNoOutcome assessorsPurpose of study; group assignment; participant characteristicsParticipants given numerical identifiersNoStatisticiansParticipant and group identitiesParticipants and groups given numerical identifiersNo**Supplemental fields for all blinded groups or individuals not mentioned above**Trial managerNot applicable. . .. . .PharmacistsNot applicable. . .. . .Laboratory techniciansParticipant identitiesParticipants given numerical identifiersOutcome adjudicatorsGroup assignmentGroups given numerical identifiersYes \[put details in text\]Data monitoring and safety committeesNot applicable. . .. . .Manuscript writersNot blinded. . .. . .^a^Other groups or individuals in a trial that were capable of being blinded should be listed in the table, and whether or not they were blinded in the study should be indicated. Individuals with dual responsibilities, such as caregiving and data collecting, should be identified by combining the entries in the same row heading^b^Although group assignment is the information most commonly withheld in a blinded trial, data assessors, such as pathologists and radiologists, are often blinded to the purpose of the trial, group assignment, and the demographic and clinical characteristics of participants whose biopsy samples or images they are interpreting^c^In many cases, authors should determine before the trial begins whether the method of blinding had a reasonable chance of being effective, including establishing the similarity between active and placebo preparations and the bioequivalent availability for two or more active drugs \[[@CR33]\]. Testing the effectiveness of blinding after the trial has ended is uninformative because the results cannot be separated from pre-trial expectations of the success of the intervention \[[@CR32]\]^d^If blinding has been compromised, authors should report the fact and indicate the potential implications the loss of blinding might have for interpreting the results

Conclusions {#Sec12}
===========

"Blinding" as a concept to reduce bias has been used for more than 200 years \[[@CR34]\], and "double-blind" as a term has been used in clinical trials for 70 years \[[@CR35]\]. Even with the substantial support in the literature for abandoning its use, finding a simple, acceptable replacement seems unlikely. Instead, eliminating the use of adjectives that impart a false specificity to the term would reduce misinterpretations, and recommending that authors report who was blinded to what and how in a standard table would require them to be more specific about which groups and individuals were blinded.
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